Knowledge surrounding inpatient dermatologic procedure costs is limited; therefore to learn more, we performed a cross-sectional analysis of dermatologic procedures contained in a publicly available Washington State Comprehensive Hospital Abstract Reporting System database from 2014. Dermatologic procedure utilization and cost were evaluated based on several parameters including demographics, length of hospital stay, payments, and payers. SAS 9.4 was used for the analysis. A total of 14,768 patients underwent dermatologic procedures in 2014 and 81.0% were white. The average age was 53 years (SD = 0.17), and the average payment for all patients who underwent dermatologic procedures was $85,059.48 (SD = $1,284.34). The average hospital length of stay was 8.91 days (SD = 0.07). The most common admission type was elective (66.2%), the most common admit source was a non-healthcare facility point of origin (78.2%), the most common primary payer was Medicare (36.2%), and the most common procedure was incision and drainage of skin and subcutaneous tissue (26.5%), followed by closure of skin and subcutaneous tissue of other sites (20%). This analysis demonstrated that inpatient dermatologic procedures are a significant driver of inpatient health care costs, and it is critical to determine factors that increase inpatient costs related to dermatologic procedures in order to develop strategies for reducing healthcare costs.
Introduction
Health care spending accounted for 17.9% of the nation's gross domestic product (GDP) in 2017, or $3.5 trillion [1] . The contribution of inpatient dermatologic procedures to this total is poorly understood. For example, the cost of dermatologic procedures among Medicare beneficiaries was $2.21 billion in 2017, with a portion arising from inpatient care [2] . We examined discharge records from community hospital visits to better understand the utilization and cost of non-disease-specific inpatient dermatologic procedures.
Materials And Methods
We performed a cross-sectional analysis of the Washington State Comprehensive Hospital Abstract Reporting System (CHARS) database to analyze the utilization and cost of inpatient dermatologic procedures performed in 2014 [3] . This database contains record-level data pertaining to inpatient and observation community hospital visits and abstracted information on discharges for civilian hospitals in the state. CHARS database collection methods have been described elsewhere [4] . This study was IRB exempt due to the de-identified and publicly available data.
All patients were adults (>18 years of age) hospitalized in Washington in 2014 who underwent a variety of dermatologic procedure. Descriptive analyses were performed on patient demographics, length of hospital stay, admission type, payment amount, and primary payer. All statistical analyses were performed using SAS 9.4 (Cary, NC).
Results
A total of 14,768 patients underwent dermatologic procedures in 2014. Descriptive characteristics of the sample are provided in Table 1 . The majority of admissions were elective (66.2%). The most common primary payer was Medicare (36.2%) followed by Medicaid (28.5%). The mean total hospitalization payment for patients undergoing dermatologic procedures was $85,059.48, and the average length of hospital stay was 8.9 days. The most common procedure was incision and drainage of skin and subcutaneous (SC) tissue (26.5%). Characteristics of patients undergoing each of the identified procedures are provided in Table 2 . Medicaid was the most common payer when incision and drainage of skin and SC tissue was performed. Skin chemosurgery had the highest average admission cost ($548,535.70) and excisional debridement had the highest aggregate cost ($5,333,677.80). 
Discussion
The majority (55.2%) of financial costs related to dermatologic care, including procedural costs, are experienced in the outpatient setting [5] . While inpatient costs contribute significantly to overall healthcare expenditures (20.1%), understanding of these costs is limited [1] . Moreover, data related to dermatologic costs in the inpatient setting primarily focus on disease-specific aggregate costs. For example, inpatient costs for care for psoriasis have been shown to be cost-prohibitive when compared to outpatient treatment (13,042 € versus 2,984 €), especially when accounting for biologic therapy use [6] .
This current analysis is unique in that it identifies dermatologic procedures performed during an inpatient admission independent of dermatologic diagnosis and reveals potential factors that may be used to stratify patients undergoing a dermatologic procedure and suggest opportunities for cost reduction. This study is limited by its regional geographic encashment. Co-morbid diagnoses and direct cost of dermatologic procedures could not be analyzed, and aggregate cost reporting may have overestimated the relative cost contribution. Finally, provider specialty and level of training were not available.
Most patients received a dermatologic procedure during an elective admission and the primary payer was either Medicare or Medicaid. Additionally, our findings support dermatologic consultation when dermatologic procedures are considered. Diagnostic procedures recommended by an appropriately consulted dermatologist yield a definitive diagnosis in up to 80% of cases. Moreover, 45% to 80% of diagnoses will change after dermatology consultation preventing unnecessary therapy and costly hospital stays [7] . Finally, dermatology consultation may also facilitate outpatient follow-up for a procedure rather than performing it during admission. Inpatient dermatologic procedures are a significant driver of inpatient health care costs. It is critical to determine factors that increase inpatient costs related to dermatologic procedures to develop strategies for reducing healthcare costs. A good initial cohort for future study would be patients receiving a dermatologic procedure during an elective admission who have Medicare or Medicaid.
Conclusions
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